Literature DB >> 17336721

Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study.

Mathew S Maurer1, Daniel Burkhoff, Linda P Fried, John Gottdiener, Donald L King, Dalane W Kitzman.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate left ventricular (LV) size and structure in elderly subjects with hypertension (HTN) and heart failure who have a normal ejection fraction (HFNEF) in a large population-based sample.
BACKGROUND: The pathophysiology of HFNEF is incompletely understood but is generally attributed to LV diastolic dysfunction with normal or reduced LV diastolic chamber size despite greater than normal filling pressures.
METHODS: In the Cardiovascular Health Study (n = 5,888), demographic and clinical characteristics and ventricular structure and function were compared in healthy normal subjects (healthy; n = 499), subjects with HTN but not heart failure (HTN; n = 2,184), and subjects with HTN and HFNEF (HFNEF; n = 167).
RESULTS: Subjects with HFNEF were older, more obese, and more often African American than healthy and HTN subjects and had a higher prevalence of diabetes, coronary heart disease, and anemia than HTN subjects. Serum creatinine and cystatin-C were increased in HFNEF subjects. Average LV diastolic dimension was significantly increased in HFNEF subjects (5.2 +/- 0.8 cm) compared with healthy (4.8 +/- 0.6 cm) and HTN (4.9 +/- 0.6 cm) subjects. As a result, average calculated stroke volume (89 +/- 25 ml vs. 78 +/- 20 ml and 80 +/- 20 ml) and cardiac output (6.0 +/- 2.0 l/min vs. 4.8 +/- 1.3 l/min and 5.1 +/- 1.4 l/min) were increased in HFNEF compared with healthy and HTN subjects, respectively.
CONCLUSIONS: As a group, HFNEF subjects have increased LV diastolic diameter and increased calculated stroke volume. They also have increased prevalence of multiple comorbidities, including anemia, renal dysfunction, and obesity, that can cause volume overload. These data suggest that extracardiac factors, via volume overload, may contribute to the pathophysiology of HFNEF in the elderly.

Entities:  

Mesh:

Year:  2007        PMID: 17336721     DOI: 10.1016/j.jacc.2006.10.061

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  62 in total

1.  Heart failure with a normal ejection fraction: treatments for a complex syndrome?

Authors:  Samuel Bernard; Mathew S Maurer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

2.  Congestion is the driving force behind heart failure.

Authors:  Maya Guglin
Journal:  Curr Heart Fail Rep       Date:  2012-09

Review 3.  Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.

Authors:  Fayez El Shear
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

4.  Aging and the brain renin-angiotensin system: relevance to age-related decline in cardiac function.

Authors:  Debra I Diz; Jasmina Varagic; Leanne Groban
Journal:  Future Cardiol       Date:  2008-05

Review 5.  The pathophysiology of heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

6.  Effect of chronic disease-related symptoms and impairments on universal health outcomes in older adults.

Authors:  Mary E Tinetti; Gail McAvay; Sandy S Chang; Yuming Ning; Anne B Newman; Annette Fitzpatrick; Terri R Fried; Tamara B Harris; Michael C Nevitt; Suzanne Satterfield; Kristine Yaffe; Peter Peduzzi
Journal:  J Am Geriatr Soc       Date:  2011-08-24       Impact factor: 5.562

Review 7.  Ventricular remodeling in heart failure with preserved ejection fraction.

Authors:  Amil M Shah
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 8.  Cell- and molecular-level mechanisms contributing to diastolic dysfunction in HFpEF.

Authors:  Kenneth S Campbell; Vincent L Sorrell
Journal:  J Appl Physiol (1985)       Date:  2015-04-24

9.  Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy.

Authors:  Mathew S Maurer; Sergio Teruya; Bibhas Chakraborty; Stephen Helmke; Donna Mancini
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

10.  The pathophysiology of diastolic heart failure.

Authors:  Thanh Trung Phan; Michael Frenneaux
Journal:  F1000 Biol Rep       Date:  2010-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.